Predictors of secukinumab treatment response and continuation in axial spondyloarthritis: results from the EuroSpA research collaboration network
04/09/2024
M. Pons1, S. Georgiadis1, M. Østergaard1,2, Z. Faizy Ahmadzay1, S. Horskjær Rasmussen1, S. Nysom Christiansen1, K. Perdan Pirkmajer3,4, Z. Rotar3,4, D. DI Giuseppe5, J. K. Wallman6, B. Gudbjornsson7,8, Ó. Pálsson6,8, F. Iannone9, B. Glintborg1,2,10, A. G. Loft11,12, K. Pavelka13,14, J. Zavada13,14, M. J. Nissen15, A. Ciurea16, H. Santos17,18, M. H. Fernandes Lourenco19,20, B. Michelsen1,21,22, P. Mielnik23, I. Castrejon24,25, L. Kuusalo26, V. Rantalaiho27, G. J. Macfarlane28, K. Laas29, I. Van d
EULAR 2024
DOI: 10.1136/annrheumdis-2024-eular.562
https://ard.bmj.com/content/83/Suppl_1/152